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ABSTRACT Two classes (site 1- and site 2-selective) of
cAMP analogs, which either alone or in combination demon-
strate a preference for binding to type II rather than type I
cAMP-dependent protein kinase isozyme, potently inhibit
growth in a spectrum of human cancer cell lines in culture.
Treatment of K-562 human leukemic cells for 3 days with 30
and 10 ,uM 8-chloroadenosine 3',5'-cyclic monophosphate
(8-Cl-cAMP) (site 1-selective) resulted in 60% and 20% growth
inhibition, respectively (with over 90% viability). N'-
Benzyl-cAMP (site 2-selective) (30 IpM) treatment resulted in
20% growth inhibition by day 3. When 8-Cl-cAMP (10 pM)
and N6-benzyl-cAMP (30 ,uM) were both added, growth was
almost completely arrested. The growth inhibition was accom-
panied by megakaryocytic differentiation in K-562 cells. The
untreated control cells expressed little or no detectable levels of
glycoprotein nwb-rn surface antigen complex. 8-Cl-cAMP (30
,uM) treatment for 3 days substantially increased the antigen
expression, while N6-benzyl-cAMP caused little or no change in
the antigen expression. When cells were treated with 8-
Cl-cAMP in combination with N6-benzyl-cAMP, antigen
expression was synergistically enhanced, and cells demon-
strated megakaryocyte morphology. By Northern blotting, we
examined the mRNA levels of the type I and type I protein
kinase regulatory subunits (RI. and Rllp), the catalytic sub-
unit, and c-myc during 8-Cl-cAMP treatment. The steady-state
level of RUp, cAMP receptor mRNA sharply increased within
1 hr of treatment and remained elevated for 3 days, while that
of the RIU receptor markedly decreased to below control level
within 6 hr and remained low during treatment. However,
8-Cl-cAMP did not affect the mRNA level of the catalytic
subunit. 8-Cl-cAMP treatment also brought about a rapid
decrease in c-myc mRNA. Thus, differential regulation of
cAMP receptor genes is an early event in cAMP-induced
differentiation and growth control of K-562 leukemia cells.
A major defect ofcancer cells is their inability to differentiate
normally (1-4). This defect may be partly reversible, and
study of such models may help to elucidate the mechanism
responsible for differentiation. The K-562 human leukemic
cell line, which carries a Philadelphia chromosome and was
established from a patient with chronic myelogenous leuke-
mia in blast crisis (5), is such a model. This cell line is
considered to consist of a multipotent hematopoietic stem
cell, since it responds to inducers of erythroid differentiation
(6-8), megakaryocytic differentiation (9, 10), and granulo-
cytic differentiation (11, 12). The cellular mechanisms re-
sponsible for these processes, however, are not known.
cAMP, an intracellular regulatory agent, has long been
considered to have a role in the control of cell proliferation
and differentiation in a variety of cell types (13-16). cAMP
exerts its effect in eukaryotes by binding to the regulatory
subunits of either type I or type II cAMP-dependent protein
kinase (17, 18). Differential expression ofthese protein kinase
isozymes has been observed during cell development, differ-
entiation, and neoplastic transformation (19-22).
Recently, we discovered that site-selective cAMP analogs,
which show a preference for binding to type II rather than
type I protein kinase of purified preparations in vitro (23, 24),
provoke potent growth inhibition, differentiation, and re-
verse transformation in a broad spectrum of human and
rodent cancer cell lines (25-27). Furthermore, these effects
were synergistically enhanced when two classes of cAMP
analog (site 1- and site 2-selective) were used in combination
(25-27). 8-Chloroadenosine 3',5'-cyclic monophosphate (8-
Cl-cAMP), the most potent site-selective cAMP analog, is
now in preclinical phase I studies at the National Cancer
Institute.
There have been no previous studies that have demon-
strated the potential for cAMP or cAMP analogs to induce
differentiation in K-562 stem cell leukemia. In this study, we
correlated the growth inhibitory effect of site-selective cAMP
analogs in K-562 cells with their effect on the induction of
differentiation as well as the expression of the regulatory and
catalytic genes of protein kinase isozymes and the growth-
associated oncogene c-myc.
MATERIALS AND METHODS
Cell Culture and Morphological Studies. K-562 cells (Amer-
ican Type Culture Collection) were grown in suspension
culture in RPMI 1640 medium supplemented with 10% fetal
bovine serum, penicillin (50 units/ml), streptomycin (500
,Ag/ml), and 1 mM glutamine (GIBCO) at 5 x 105 cells per ml
in a humidified 5% CO2 atmosphere. For cell growth exper-
iments, cells were treated with cAMP analogs (28) once at 3
hr after seeding, and cell counts were performed in duplicate
on a Coulter Counter at indicated times. Cell viability was
determined by the trypan-blue exclusion method. Cell mor-
phology studies were performed on cytocentrifuged slides
stained with Wright-Giemsa stain.
Abbreviations: 8-Cl-cAMP, 8-chloroadenosine 3',5'-cyclic mono-
phosphate; RI,, and RII,9, type I and II protein kinase regulatory
subunits; Ca, protein kinase catalytic subunit.
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Cell Surface Antigen Analysis. Cell surface antigens were
analyzed by indirect immunofluorescence, using a FAC-
STAR flow cytometer (Becton Dickinson FACS Systems)
(29). The following antibodies were used: B4, My4, My7,
My9 (Coulter Immunology); 10E5 (kindly provided by Barry
Coller, University of New York, Stony Brook); and anti-
glycophorin A (Amac, Westbrook, ME). After incubation at
4°C with the primary antibody, cells (104 cells per sample)
were washed and allowed to react with fluorescein isothio-
cyanate-conjugated goat anti-mouse immunoglobulin (Kirke-
gaard and Perry Laboratories, Gaithersburg, MD) at 4°C. A
nonimmune mouse ascites preparation was used as a control
for nonspecific reactivity of the primary antibody. After
several washes, cells were analyzed on a FACSTAR flow
cytometer.
Northern Blot Analysis. Total cellular RNA was obtained
from cells (108 cells washed twice with Dulbecco's phos-
phate-buffered saline) lysed with 4 M guanidium isothiocya-
nate by centrifugation through a CsCl cushion as described
by Chirgwin et al. (30). Total cellular RNA (20 ,ug per lane)
was denatured in 50% formamide/6% formaldehyde
(vol/vol) by heating for 15 min at 50°C followed by 15 min on
ice, fractionated by electrophoresis through a 1.5% agarose
gel containing 6.7% formaldehyde in 20 mM sodium phos-
phate, pH 7.0, and blotted by the method of Thomas onto
nitrocellulose filters (31). Hybridization was performed at
37°C over 16 hr in 50% formamide/1x Denhardt's
solution/4x SSC (Denhardt's solution = 0.02% bovine
serum albumin/0.02% Ficoll/0.02% polyvinylpyrrolidone;
SSC = 0.15 M NaCl/0.015 M sodium citrate). After hybrid-
ization, filters were washed in 0.2x SSC/0.1% NaDodSO4 at
65°C three times per hr and once per hr at 650C with 1 x SSC.
Autoradiography was performed at -70°C with Kodak X-
Omat AR film. The nick-translated probes were obtained
from Lofstrand Laboratories (Gaithersburg, MD). The type
I protein kinase regulatory subunit RI, (see ref. 32 for
nomenclature) probe was a 0.6-kilobase (kb) Pst I fragment
(mouse), entirely from inside the open reading frame (33), and
the catalytic subunit (Ca) probe was a 0.6-kb EcoRI fragment
(mouse) containing a 3' coding region and about 160 base
pairs (bp) of 3' nontranslating sequence (34) (kindly provided
by S. McKnight, University of Washington, Seattle). The
human RIIp probe was a 1.6-kb BamHI fragment derived
from a cDNA clone (35), spanning the 3' half of the open
reading frame and part of the nontranslating region. The
c-myc probe was a recombinant plasmid pRyc 7.4 (36),
containing a portion of c-myc exon II and exon III (kindly
provided by C. M. Croce, Wistar Institute, Philadelphia).
RESULTS
Effect of cAMP Analogs on Cell Growth. Site-selective
cAMP analogs inhibit the growth of several human leukemic
cell lines in a concentration-dependent manner (26). The
growth curves of the K-562 leukemic cell line in the absence
and presence of cAMP analogs are shown in Fig. 1A.
8-Cl-cAMP (site 1-selective) at 30 uM produced 60% growth
inhibition by 72 hr. N6-Benzyl-cAMP (site 2-selective) at 30
,uM produced a 20% growth inhibition. When 8-Cl-cAMP (10
,uM), which alone gave a 20% growth inhibition (26), was
added in combination with N6-benzyl-cAMP (30 ,uM), cell
growth was almost completely stopped. Thus, the growth of
K-562 leukemic cells was strongly inhibited by site 1-
selective 8-Cl-cAMP alone and also synergistically inhibited
by site 1- and site 2-selective cAMP analogs in combination,
as was previously shown (25) in human colon and breast
cancer cell lines.
Effect of cAMP Analogs on Differentiation. We examined
the effect of site-selective cAMP analogs on the expression of
differentiation markers in K-562 cells to determine whether
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FIG. 1. Effect ofcAMP analogs on the growth and differentiation
of K-562 cells. (A) Growth curves in the absence and presence of the
cAMP analogs N6-benzyl-cAMP (N6-Benzyl) and 8-Cl-cAMP (8-Cl)
at given concentrations. Points represent the means of triplicate
determinations; bars, SD. (B) Flow cytometric analysis of glycopro-
tein Ilbr-41a surface marker. Cells were treated with cAMP analogs
(30 ,uM) as in A once at 3 hr after seeding, were harvested after 3
days, and were allowed to react with the monoclonal antibody 10E5
(specific for the glycoprotein IIba-III complex of megakaryocytes).
The indirect immunofluorescence was measured by FACSTAR flow
cytometry.
growth-inhibited cells are more differentiated than the un-
treated cells. Megakaryocytic differentiation was assessed by
flow cytometric analysis with the monoclonal antibody lOE5,
which recognizes the glycoprotein Ilba-III complex, a spe-
cific megakaryocytic marker expressed in the differentiation
of this lineage (37, 38). Treatment for 3 days with 8-Cl-cAMP
(30 FM) induced a marked increase in the fraction of cells
positive for the glycoprotein Ilb;-IIa antigen' (Fig. 1B, Table
1). Untreated cells expressed little or no detectable level of
this antigen. N6-Benzyl-cAMP (30 liM) treatment alone did
not induce an appreciable increase of this antigen expression
(data not shown), but when N6-benzyl-cAMP (30 ,uM) was
added with 8-Cl-cAMP (10-30 juM), the majority of cells
expressed this antigen (Fig. 1B). This agrees with the
Table 1. Modulation of differentiation markers in K-562 cells by
8-Cl-cAMP
No. of positive cells
Cell lineage Surface marker Control 8-Cl-cAMP
Megakaryocytic Glycoprotein IIbr11a - + +
Erythrocytic Glycophorin A + + +
Lymphocytic B4 - +
Myelomonocytic My4 + +
Myelocytic My7 + + +
Myelocytic My9 + + +
Cells were treated with 8-Cl-cAMP (30 ,uM) once at 3 hr after
seeding, were harvested at 3 days, and were allowed to react with
monoclonal antibodies to the indicated surface markers. Indirect
immunofluorescence was determined by flow cytometry. Number of
positive cells: -, <15%; +, -30%o; ++, -50%1.
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synergistic effect of 8-Cl-cAMP and N6-benzyl-cAMP on
growth inhibition (Fig. 1A). Moreover, glycoprotein Hb-lla
expression was accompanied by morphological changes typ-
ical of megakaryocytes (data not shown). 8-Cl-cAMP also
induced B4 lymphocytic marker antigen, but it either de-
creased or produced no change in the expression of myelo-
cytic and monocytic differentiation antigens (Table 1). Thus,
8-Cl-cAMP induced megakaryocytic differentiation in K-562
leukemic cells in a lineage-specific manner, as was shown
previously with phorbol esters (39).
mRNA Levels of Protein Kinase Subunits. mRNA levels for
the regulatory and catalytic subunits of cAMP-dependent
protein kinase isozymes were examined in K-562 cells after
treatment with 8-Cl-cAMP. The RNA filters prepared were
probed with the radioactive cDNAs of protein kinase sub-
units; the Northern blot analysis is shown in Fig. 2. The
mouse RI,, (regulatory subunit 6fprotein kinase type I) cDNA
probe detected 3.0- and 1.7-kb mRNA bands in the untreated
control K-562 cells.' 8-Cl-cAMP treatment resulted in a
decrease in the intensity of both bands to 50o of that of
untreated control cells by 6 hr. after a 50%6 transient increase
at 1 hr (see densitometry data in Fig. 2). With the human RIIV
(the Mr 51,000 regulatory subunit of protein kinase type II)
cDNA probe, a single mRNA band at 3.2 kb was detected.
Within 1 hr of 8-Cl-cAMP treatment, the band intensity
increased 4-fold over the control, and the mRNA remained
elevated during treatment (see densitometry data in Fig. 2).
Thus, the RIa and RIIq mRNA levels changed in an inverse
manner in response to 8-Cl-cAMP treatment. Using the
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FIG. 2. Northern blot analysis of the regulatory (RI, and Rh11)
and catalytic (Ca) mRNAs in K-562 cells during 8-Cl-cAMP treat-
ment. Cells were treated with 8-,Cl-cAMP (30 AM) once at 3 hr after
seeding and harvested at given times after treatment, and total RNA
was extracted by the guanidinium isothiocyanate method. Twenty
micrograms of total RNA per lane were run on 1.5% agarose/
formaldehyde gels and blotted on nitrocellulose. The bar graph
represents densitometric scanning of the autoradiograms; the data
are expressed as X-fold of the levels in treated control cells. (Both
3.0- and 1.7-kb bands were counted for RIa mRNA quantification.)
Similar data were obtained by scintillation counting of bands. C,
untreated control cells grown for 3 days; H, hour; D, days.
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C 1.0±0.15
IH 0.1 ± 0.02
6H 0.1 ± 0.02
3D 0.02 ± 0.005
Fic. 3. Northern blot analysis of c-myc mRNA in K-562 cells
during 8-Cl-cAMP (30 uM) treatment. Cells were treated and
harvested at the given times after treatment, and the total RNA
fractionated on agarose gels was blotted on nitrocellulose as de-
scribed in the legend to Fig. 2. The data in the table were from
densitometry of autoradiograms, where the untreated control cell
level (C) was set as 1.0 arbitrary unit; the values represent mean ±
SEM of six separate experiments.
mouse cDNA probe for CQ, we detected a 2.4-kb mRNA. The
band intensity showed no appreciable change during 8-
Cl-cAMP treatment (Fig. 2).
c-myc mRNA Level. Nuclei-associated oncogenes are reg-
ulated by proliferative signals (40), and a decrease in c-myc
mRNA has been shown to be a critical event in differentiation
of leukemic cells (41). 8-Cl-cAMP treatment of K-562 cells
brought about a sharp decrease in the c-myc mRNA: within
1 hr of treatment, the mRNA decreased to 0.1 of the control,
and the level was almost undetectable (<0.02 control) by 3
days (Fig. 3).
DISCUSSION
We have shown here that site-selective cAMP analogs induce
growth inhibition and differentiation in the K-562 chronic
myelocytic leukemic cell line. Two classes ofcAMP analogs,
the site 1-selective 8-Cl-cAMP and the site 2-selective N6-
benzyl-cAMP, demonstrated a synergistic effect when com-
bined. This synergism has previously been found in differ-
entiation of HL60 and MOLT 4 leukemia cell lines (26) and
in the inhibition of various types of human cancer cell lines
(25). This analog effect has been correlated with the selective
increase of type II protein kinase holoenzyme and its RII
regulatory subunit, and the decrease of type I protein kinase
and the RI regulatory subunit in the cancer cells (25-27); this
parallels the analogs' preferential binding to protein kinase
type II rather than type I in vitro (42-44).
The results of this study demonstrate that the effect of
8-Cl-cAMP on growth inhibition and differentiation corre-
lates with differential expression of the genes for the regu-
latory subunits (RI, and RII) of protein kinase isozymes.
The analog treatment induced an increase in the RII3 mRNA
along with a decrease in the RIa mRNA. These changes
occurred within a few hours of analog treatment, indicating
that the changes are early events rather than the conse-
quences of growth inhibition and differentiation.
The occurrence of a selective increase in the expression of
the RI,9 gene but not in that of the RI, gene during
differentiation of K-562 cells is in agreement with the results
ofother studies. In Friend erythroleukemic cells, two species
of the regulatory subunits of type II protein kinase, Rlla (Mr
= 54,000) and R113 (MW = 51,000-52,000), were expressed,
but only the concentration of RI11 increased in response to
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treatment with 8-bromo-cAMP and methylisobutylxanthine
or when stimulated to differentiate (45). Increase of RIle
mRNA has also been demonstrated during hormonal differ-
entiation of rat granulosa cells (46).
The analog effect on the changing levels ofthe R I3 and RIa
mRNAs may be due to changes in gene transcription,
stabilization of these mRNAs, or both. In LS-174T human
colon cancer cells, the 8-Cl-cAMP-induced growth inhibition
accompanied an increased transcription of the R Ip gene anddecreased transcription of the RI. gene (44). However, these
changes in the rates of transcription of RI. and RIIp werepreceded by nuclear translocation of R1I3 protein, which
occurred within 10 min of 8-Cl-cAMP treatment, while the
changes in the transcription ofthe cAMP receptor genes were
not detected (44). Nuclear translocation of cAMP receptor
proteins, which has been previously observed during cell
development (19), tumor regression (22), and reverse trans-
formation (47), suggests the possible role of these proteins in
gene regulation.
Both cAMP-dependent protein kinase and protein kinase C
have been shown to play a role in the transcription regulation
of the cAMP-responsive element (48). We showed here that
site-selective cAMP analogs induced megakaryocytic differ-
entiation in K-562 cells in a lineage-specific manner, as was
shown previously by phorbol esters (39). The fact that both
cAMP analogs and phorbol esters induce megakaryocytic
differentiation of leukemic cells suggests either separate or
coordinated roles of cAMP-dependent protein kinase and
protein kinase C in cell differentiation. During 8-Cl-cAMP-
induced differentiation of K-562 cells, a marked decrease in
c-ryc mRNA also occurred, indicating that 8-Cl-cAMP
antagonized proliferative signal(s). The results reported here
suggest that cAMP receptor proteins may have a major role
in regulating the cascade of events that affect expression of
the differentiation program in leukemic cells.
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